GenMark Diagnostics (GNMK) PT Raised to $19 at Needham & Company After Positive Preannouncement
Tweet Send to a Friend
Needham & Company analyst Mike Matson raised the price target on GenMark Diagnostics (NASDAQ: GNMK) to $19.00 (from $15.00) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
